Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.4M Buy
15,741
+11,374
+260% +$2.18M 0.03% 277
2026
Q1
$801K Buy
+4,367
New +$805K 0.01% 347
2023
Q4
Sell
-6,795
Closed -$1.75M 430
2023
Q3
$1.75M Buy
6,795
+1,031
+18% +$276K 0.04% 304
2023
Q2
$1.64M Sell
5,764
-2,618
-31% -$779K 0.04% 278
2023
Q1
$2.33M Buy
8,382
+1,359
+19% +$376K 0.06% 266
2022
Q4
$1.94M Buy
+7,023
New +$1.98M 0.06% 271

Other funds holding BIIB

LBP AM's BIIB Position: Q2 2026 in Review

LBP AM increased its Biogen (BIIB) stake by 260% in Q2 2026, buying an estimated $2.18M and bringing the position to 15,741 shares worth $3.4M. The position accounts for 0.03% of the portfolio, ranked #277.

LBP AM first reported a position in BIIB in Q4 2022 and has held it in 6 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • LBP AM held 15,741 shares of Biogen worth $3.4M as of Q2 2026.
  • LBP AM bought 11,374 Biogen shares in Q2 2026, an estimated $2.18M.
  • Biogen made up 0.03% of LBP AM's portfolio in Q2 2026, its #277 holding.
  • LBP AM first reported a position in Biogen in Q4 2022 and has held it in 6 quarters since.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on LBP AM's 13F filing for Q2 2026, filed 24 Jul 2026.